Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7129232 | CUBIST PHARMS LLC | Cephem compounds |
May, 2028
(4 years from now) | |
US8476425 | CUBIST PHARMS LLC | Tazobactam arginine compositions |
Sep, 2032
(9 years from now) | |
US8685957 | CUBIST PHARMS LLC | Tazobactam arginine compositions |
Sep, 2032
(9 years from now) | |
US8906898 | CUBIST PHARMS LLC | Solid forms of ceftolozane |
May, 2034
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9724353 | CUBIST PHARMS LLC | Methods for treating intrapulmonary infections |
Sep, 2032
(8 years from now) | |
US10028963 | CUBIST PHARMS LLC | Methods for treating intrapulmonary infections |
Sep, 2032
(8 years from now) | |
US11278622 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(10 years from now) | |
US9872906 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(10 years from now) | |
US8968753 | CUBIST PHARMS LLC | Ceftolozane-tazobactam pharmaceutical compositions |
Mar, 2034
(10 years from now) | |
US10420841 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(10 years from now) | |
US9320740 | CUBIST PHARMS LLC | Ceftolozane-tazobactam pharmaceutical compositions |
Mar, 2034
(10 years from now) | |
US10376496 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(10 years from now) | |
US10933053 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(10 years from now) | |
US10125149 | CUBIST PHARMS LLC | Synthesis of cephalosporin compounds |
Aug, 2035
(11 years from now) |
Zerbaxa is owned by Cubist Pharms Llc.
Zerbaxa contains Ceftolozane Sulfate; Tazobactam Sodium.
Zerbaxa has a total of 14 drug patents out of which 0 drug patents have expired.
Zerbaxa was authorised for market use on 19 December, 2014.
Zerbaxa is available in powder;intravenous dosage forms.
Zerbaxa can be used as treatment of ventilator-associated bacterial pneumonia; treatment of hospital-acquired bacterial pneumonia, treatment of hospital-acquired bacterial pneumonia; treatment of ventilator-associated bacterial pneumonia, methods of treating bacterial illnesses; methods for treating bacterial infections, treatment of complicated urinary tract infection; treatment of complicated intra-abdominal infection, treatment of ventilator-associated bacterial pneumonia in patients with end-stage renal disease on hemodialysis; treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis, methods of treating bacterial illnesses, treatment of complicated urinary tract infection in patients with end-stage renal disease on hemodialysis; treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis, treatment of hospital-acquired bacterial pneumonia (habp); treatment of ventilator-associated bacterial pneumonia (vabp), treatment of complicated urinary tract infection, including pyelonephritis; treatment of complicated intra-abdominal infection.
Drug patent challenges can be filed against Zerbaxa from 2023-12-20.
The generics of Zerbaxa are possible to be released after 14 August, 2035.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 19, 2019 |
New Patient Population (NPP) | Apr 21, 2025 |
Generating Antibiotic Incentives Now (GAIN) | Dec 19, 2024 |
Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient
NCE-1 date: 2023-12-20
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hospital-acquired bacterial pneumonia; Treatment of ventilator-associated bacterial pneumonia; Treatment of hospital-acquired bacterial pneumonia (habp); Treatment of ventilator-associate...
Dosage: POWDER;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic